Making a case for del(1p) as a high‐risk abnormality in multiple myeloma-Reference-Cited by-同舟云学术

Making a case for del(1p) as a high‐risk abnormality in multiple myeloma

Published:2023-06-06 Issue:16 Volume:129 Page:2450-2452
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Schmidt Timothy M.¹^ORCID

Affiliation:

1. University of Wisconsin Carbone Cancer Center Madison Wisconsin USA

Abstract

Chromosome 1 abnormalities are associated with worse outcomes in multiple myeloma. In the accompanying retrospective analysis, the combination of both gain(1q21) and del(1p13.3) had a greater impact on outcomes compared to either abnormality on its own.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

2. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

3. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

4. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China;Cancer Medicine;2024-09